Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating axicabtagene ciloleucel as first-line therapy for high-risk diffuse large B-cell lymphoma has completed, with results posted in July …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-08